Nichole Tucker

Both pediatric brain cancers and sarcomas have an extremely dismal outcome in the relapse setting, according to Catherine Bollard, MD. A new Cancer Grand Challenge aims to address the issue with the development of new therapies.

The novel FLT3 inhibitor, tuspetinib, will be investigated further in patients with FLT3-positive acute myeloid leukemia.

An investigational immunotherapy triplet combination is showing promise for the treatment of advanced solid tumors. Recruitment for the phase 2 study continues.

Topline results from the phase 2 TRANSCEND CLL 004 trial hint that lisocabtagene maraleucel may be active in relapsed or refractory chronic lymphocytic leukemia.

According to experts, results from the INTRIGUE study have shown the utility of ctDNA next-generation sequencing for patients with advanced gastrointestinal stromal tumor.

Phase 2 FOENIX-CCA2 study results further confirm the safety and efficacy of futibatinib for the treatment of previously treated patients with advanced/metastatic intrahepatic cholangiocarcinoma with FGFR2 fusions or rearrangements.

A speedy FDA review of the approval application for avapritinib for indolent systemic mastocytosis has commenced.

The combination use of encorafenib plus cetuximab and chemotherapy appeared to be safe and effective in treating patients with BRAF V600E-mutant metastatic colorectal cancer.

Due to its potential to fill a treatment gap in the HER-low and HER-positive endometrial cancer space, DB-1303 now has an FDA fast track designation.

MOUNTAINEER study results have wowed the FDA, leading to an accelerated FDA approval of tucatinib plus trastuzumab as RAS wild-type, HER2-positive unresectable or metastatic colorectal cancer treatment.

The COVALENT-102 study has started BMF-219 treatment in patients with KRAS-mutated, advanced solid tumors.

In IMbrave050, the risk of disease recurrence or death was decreased with adjuvant atezolizumab and bevacizumab compared with active surveillance in patients with early-stage hepatocellular carcinoma.

Administering toripalimab with a platinum-based chemotherapy doublet around the time of surgery may extend event-free survival in patients with resectable non–small cell lung cancer.

Months after the FDA granted accelerated approval to dostarlimab for this rectal cancer indication, phase 2 data have confirmed its efficacy and safety.

The ability to modify disease in patients with myelofibrosis was signaled in the REFINE study. The combination also displayed positive efficacy and was tolerable.

In an interview with Targeted Oncology, Ariel Perez, MD, explained the outcomes of patients with R/R large B-cell lymphoma who were treated with Pola-BR in the real-world setting, and the key takeaways from a single-institution study.

In an interview with Targeted Oncology, Guenther Koehne, MD, PhD provided a detailed explanation on the impact of cytomegalovirus reactivation post-transplant, cytomegalovirus reactivation prevention, and refractory cytomegalovirus reactivation.

The phase 1 study of ADXS-504 for the treatment of early prostate cancer is ongoing and new patients with be enrolled to test a higher dose level.

Patients with cancer at the end of their life may receive different pain management based on their race/ethnicity. A study has revealed fewer prescriptions and lower doses for 2 racial/ethnic groups.

The investigational drug, CFI-402257, has earned the FDA’s attention for promising preclinical results, and is now under investigation in a phase 1 study.

Based on topline results from tovorafenib in the FIREFLY-1 study, the developer plans to file a new drug application with the FDA.

The primary end point of overall survival improvement has been reached in the phase 3 LUNAR study, which is evaluating Tumor Treating Fields in combination with standard therapies for the treatment of stage IV non–small cell lung cancer.

INTRIGUE study results show that patients with gastrointestinal stromal tumor who harbor certain KIT mutations have significantly improved responses and survival with ripretinib treatment.

New results from the advanced pancreatic cancer cohort of the CodeBreaK 100 trial show positive efficacy and safety.

The CSP-targeting antibody, ZB131, is being investigated in a phase 1/2 study of patients with pancreatic cancer and other solid tumors.

The FDA has not made a decision on the approval application for toripalimab plus chemotherapy or toripalimab monotherapy for the treatment of advanced recurrent or metastatic nasopharyngeal carcinoma.

In an interview with Targeted Oncology, Matthew A. Ingham, MD, explains the uniqueness of uterine sarcomas and how years of research around these tumors have led to advances in precision medicine for patients.

New published findings from the phase 1/2 KRYSTAL-1 study have caught the attention for the FDA.

In an interview with Targeted Oncology™, R. Michael Tuttle, MD, discussed the plethora of treatment options for thyroid cancer as well as overtreatment and undertreatment of the disease.

VIKTORIA-1 is a phase 3 study evaluating treatment with gedatolisib plus fulvestrant with or without palbociclib in patients with HR-positive, HER-negative breast cancer.